Maureen O'Brien, MD

Professional Titles

• Professor
• Leukemia/Lymphoma Program Leader

Publications

• Rubinstein JD, O'Brien MM. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol. 2023;14:1237738. PubMed PMID: 37600823
• Taylor ZL, Miller TP, Poweleit EA, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Chavana A, Bernhardt MB, Schafer ES, O'Brien MM, Castellino SM, Ramsey LB. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023 Nov;16(11):2130-2143. PubMed PMID: 37503924
• Rubinstein JD, Breese EH, Krupski MC, O'Brien MM, Dandoy CE, Mizukawa B, Khoury R, Norris RE, Davies SM, Phillips CL. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplant Cell Ther. 2023 May;29(5):311.e1-311.e7. PubMed PMID: 36809824
• Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023 Jan;37(1):53-60. PubMed PMID: 36310183
• LeBlanc FR, Breese EH, Burns KC, Chang EK, Jones LM, Lee L, Mizukawa B, Norris RE, O'Brien MM, Phillips CL, Perentesis JP, Rubinstein J, Pommert L. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. Br J Haematol. 2024 Jul 31. [Epub ahead of print] PubMed PMID: 39082439
• Chavana AN, Taylor ZL, DeGroote N, Lindsay HB, Sauer HE, Mason EJ, Schafer ES, Miller TP, Castellino SM, Pommert L, O'Brien MM, Ramsey LB, Bernhardt MB, Brown AL. Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct;71(10):e31213. PubMed PMID: 39039774
• Gore L, O'Brien MM. Only the beginning: 50 years of progress toward curing childhood cancer. Cell. 2024 Mar 28;187(7):1584-1588. PubMed PMID: 38552608
• Wintering A, Ishiyama K, Tamaki S, Tamaki C, Fandel J, Ji L, Wood BL, Shah NN, Yuan CM, O'Brien MM, Loh ML, Diaz-Flores E. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2023 Jan 24;7(2):251-255. PubMed PMID: 35500285
• Rubinstein JD, O'Brien MM. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol. 2023;14:1237738. PubMed PMID: 37600823
• Taylor ZL, Miller TP, Poweleit EA, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Chavana A, Bernhardt MB, Schafer ES, O'Brien MM, Castellino SM, Ramsey LB. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023 Nov;16(11):2130-2143. PubMed PMID: 37503924
• Raghuram N, Hasegawa D, Nakashima K, Rahman S, Antoniou E, Skajaa T, Merli P, Verma A, Rabin KR, Aftandilian C, Kotecha RS, Cheuk D, Jahnukainen K, Kolenova A, Balwierz W, Norton A, O'Brien M, Cellot S, Chopek A, Arad-Cohen N, Goemans B, Rojas-Vasquez M, Ariffin H, Bartram J, Kolb EA, Locatelli F, Klusmann JH, Hasle H, McGuire B, Hasnain A, Sung L, Hitzler J. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023 Nov 14;7(21):6532-6539. PubMed PMID: 36735769
• Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, M O'Brien M, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Dec;69(12):e29999. PubMed PMID: 36215217
• Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, O'Brien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller TP. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 Nov;69(11):e29937. PubMed PMID: 36083863
• O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 Mar 20;40(9):956-967. PubMed PMID: 35007127
• Rubinstein JD, Breese EH, Krupski MC, O'Brien MM, Dandoy CE, Mizukawa B, Khoury R, Norris RE, Davies SM, Phillips CL. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplant Cell Ther. 2023 May;29(5):311.e1-311.e7. PubMed PMID: 36809824
• Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023 Jan;37(1):53-60. PubMed PMID: 36310183
• Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, O'Brien MM, Singh N, Lynch KW, Ruella M, Barash Y, Tasian SK, Thomas-Tikhonenko A. Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discov. 2022 Mar 1;3(2):103-115. PubMed PMID: 35015683
• Wintering A, Ishiyama K, Tamaki S, Tamaki C, Fandel J, Ji L, Wood BL, Shah NN, Yuan CM, O'Brien MM, Loh ML, Diaz-Flores E. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2023 Jan 24;7(2):251-255. PubMed PMID: 35500285
• Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, Brodersen L, Loken M, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021 Dec 9;138(23):2337-2346. PubMed PMID: 34320162
• Rubinstein JD, Shah R, Breese EH, Burns KC, Mangino JL, Norris RE, Lee L, Mizukawa B, O'Brien MM, Phillips CL, Perentesis JP, Pommert L, Absalon MJ. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatr Blood Cancer. 2021 Aug;68(8):e29126. PubMed PMID: 34019326

Practice Locations

• Children's Hospital Colorado

Specialty Information

• Pediatric Hematology / Oncology, Board Certification (2009)

• Cancers - Leukemia (Childhood)
• Cancers
• Cancers - Lymphoma